PI3K/AKT/mTOR Pathway Inhibitors in the Treatment of HR+/HER2- Metastatic Breast Cancer – Live

Description

Program Description

---

Take Me to the Event Registration

The goal of this program is to close the knowledge gaps in the care of HR+/HER2- MBC patients for healthcare professionals (HCPs) to understand the therapeutic potential of PI3K/ AKT/mTOR pathway inhibitors. This activity will focus on the following:

HR+/HER2- MBC Testing: Hybrid capture-based next generation sequencing (NGS) assays (FoundationOne®, FoundationOne®CDx, or FoundationOne®Liquid CDx) CLIA-certified, College of American Pathologists (CAP)-accredited laboratory (Foundation Medicine, Inc.) -Guideline update

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR+/HER2- MBC.

HR+/HER2- MBC – First-line cyclin-dependent kinase 4/6 (CDK4/6) combinations with PIK3CA mutation (PIK3CAmt)

• Palbociclib plus fulvestrant versus placebo plus fulvestrant
• Abemaciclib plus fulvestrant versus placebo plus fulvestrant

HR+/HER2- MBC – Second-line therapies with PIK3CA/AKT1/PTEN alterations

• After progression on endocrine therapy (ET) plus CDK4/6 inhibitors, second-line options for patients with PIK3CA, AKT1, or PTEN alterations include inavolisib, alpelisib, capivasertib, and everolimus.
• Investigational therapies for HR+/HER2- MBC with PIK3CA/AKT1/PTEN alterations – Gedatolisib
• Mutant-selective inhibitors – RELAY 2608, STX-478, LOXO-783, TOS-358

Adverse Effects (AEs) – Management of associated toxicities with the inhibitors of the PI3K/AKT/mTOR pathway

• Hyperglycemia and hyperinsulinemia
• Stomatitis
• Maculopapular rash
• Cardiovascular events (CVAEs)

Agenda

---

Overview of the PI3K/AKT/mTOR pathway and genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR+/HER2- MBC
Arielle Medford, MD

Discuss the current and emerging evidence supporting the use of PI3K/AKT/mTOR pathway inhibitors in the treatment of HR+/HER2- MBC, and management of adverse events
Antonio Giordano, MD, PhD

Intended Audience

---

This activity is designed to meet the educational needs of medical oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other healthcare professionals who treat patients with HR+/HER2- Metastatic breast cancer (MBC).

Commercial Supporter

---

Supported by an educational grant from AstraZeneca Pharmaceuticals